Engflag

Opas

Quick links to important sections

Opas

Opas_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Opas

Property Description
Active Ingredients Calcium Carbonate, Magnesium Carbonate, Magnesium Trisilicate, Sodium Bicarbonate
Pharmacological Class Combination Antacid, Gastrointestinal Agent
Form Oral Pharmaceutical Preparation (e.g., tablet, suspension)
Route Oral
Origin Synthetic/Mineral-derived inorganic salts

Defining Opas: Type and Pharmacological Class

Opas is a multi-component pharmaceutical preparation clinically recognized as a Combination Antacid and a Gastrointestinal Agent. Its primary function is the chemical neutralization of excess hydrochloric acid in the stomach. Antacids operate by directly reducing gastric acidity, a mechanism distinct from drugs that inhibit acid production. As a combination product, Opas strategically blends various inorganic salts to ensure both a rapid onset of action and prolonged buffering capacity upon oral administration. This staggered release of neutralizing capacity is a key differentiating feature in comprehensive acidity management.

Opas Composition: Four Active Ingredients

The preparation’s efficacy rests on its four primary active ingredients, all derived from synthetic/mineral inorganic salts: Calcium Carbonate, Magnesium Carbonate, Magnesium Trisilicate, and Sodium Bicarbonate. This specific chemical composition is designed to exploit the differing neutralization kinetics of each component. For instance, Calcium Carbonate acts as a powerful, rapid acid-buffering agent, while the less soluble Magnesium Trisilicate contributes to sustained neutralization. This complexity ensures the preparation addresses both the immediacy and persistence of acid-related distress, offering a wider spectrum of relief than simple, single-salt formulas.

General Purpose and Triple Action Principle

The general therapeutic purpose of Opas is the relief of discomfort associated with hyperacidity, which commonly presents as symptoms like heartburn and acid indigestion (dyspepsia). The formulation is engineered around a triple-action principle to achieve this. Fast-acting components, such as Sodium Bicarbonate, ensure rapid acid buffering, while the slower dissociation of other salts provides sustained neutralization. Additionally, the silicate compound, Magnesium Trisilicate, contributes a unique physical function by reacting to form a gel-like substance that offers protective mucosal action on the digestive lining.

What side effects are possible with Opas?

Possible Side Effects and Safety Information

The safety profile of Opas (Pneumococcal 21-valent Conjugate Vaccine) is documented in official government regulatory documents, which classify adverse events by frequency and potential seriousness.

Adverse Reaction Scope

Classification Examples of Reactions Systems Involved
Very Common (≥10%) Injection-site pain, fatigue, headache, muscle pain (myalgia), injection-site erythema (redness) General Disorders, Musculoskeletal, Nervous System
Common (1% to <10%) Fever (pyrexia), chills, joint pain (arthralgia), nausea General Disorders, Musculoskeletal, Gastrointestinal

Serious Adverse Reactions: The regulatory labeling highlights the potential for severe allergic reactions (e.g., anaphylaxis). Rare instances of events such as bronchospasm and injection-site cellulitis have also been noted in clinical trial documentation.

Safety-Related Restrictions or Limitations: Use is contraindicated in individuals with a history of a severe allergic reaction to any component of the vaccine or to diphtheria toxoid. Vaccination should be postponed in persons with an acute severe febrile illness.

Population-Specific Safety Considerations: The safety and effectiveness have not been established in individuals younger than 18 years of age. Data on use during pregnancy and lactation are insufficient, and safety has not been formally established in these populations.

Connection to the Overall Safety Profile

The official safety information structures the risks by noting that most adverse effects are common, expected, and temporary reactions related to the immunization process. These frequent but non-serious events are distinct from the rare but critical events, such as anaphylaxis, which define the absolute safety restriction for the drug.

Overdose and Emergency Response

The official regulatory documents state that overdosage with Opas is considered unlikely. This is directly related to the product's pharmaceutical presentation as a pre-filled, single-dose syringe. The administration of a dose higher than recommended is largely undocumented; consequently, regulatory agencies report that no specific clinical signs or symptom clusters associated with Opas overdosage have been formally recorded in the prescribing information. Furthermore, no specific physiological system effects or severe outcomes are formally described in the Overdose sections of the regulatory labels reviewed.

When Immediate Medical Help is Required

Despite the low likelihood, any suspected instance of over-administration requires immediate medical attention. In the event of a suspected overdose, regulatory guidance mandates that a healthcare professional, hospital emergency department, or regional poison control centre must be contacted immediately for management. This action constitutes the core emergency response documented in the official prescribing information.

Supportive Management and Antidote

The regulatory labels refer to the general "management" of a suspected overdose; however, no specific antidote or detailed procedural steps are documented for Opas in the official regulatory information. Management of any suspected overdosage is supportive and should be guided by professional medical assessment. No population-specific monitoring or special considerations for overdose are noted in the official labeling.

Therapeutic Uses of Opas

Quick Facts

  • Approved Use: Active immunization to help prevent certain pneumococcal diseases, including invasive disease and pneumonia.
  • Target Population: Authorized for use in individuals 18 years of age and older.
  • Therapeutic Role: Contributes to the reduction of serious infections caused by specific Streptococcus pneumoniae serotypes.

Opas (also referred to as CAPVAXIVE) is a therapeutic agent used for active immunization in adults aged 18 years and older. The primary benefit of this treatment is to aid in the prevention of illnesses associated with the bacterium Streptococcus pneumoniae.

Specifically, Opas is indicated for the prevention of invasive pneumococcal disease, which refers to serious infections like bacteremia (bloodstream infection) and meningitis. It is also utilized for the prevention of pneumonia caused by a specified group of pneumococcal serotypes. The agent is designed to elicit an immune response against these specific serotypes, thereby offering protection. The treatment is intended to reduce the risk of these serious conditions in the authorized age group. The indication for the prevention of pneumonia is based on observed immune responses. Patients should consult with a healthcare professional to determine if this therapy is appropriate for their specific health status and vaccination schedule.

Eligibility and Restrictions for Use

Who can and cannot use Opas?

Opas is officially authorized for use only in individuals 18 years of age and older. The safety and effectiveness of the vaccine have not been established in children or adolescents younger than 18 years, making it an ineligible population according to regulatory documents.

Use of Opas is contraindicated for any individual with a history of a severe allergic reaction (anaphylaxis) to any component of the vaccine or to diphtheria toxoid.

Conditional Use and Restrictions

Administration is subject to several conditional restrictions based on clinical state. Vaccination should be postponed in individuals experiencing an acute severe febrile illness or acute infection. Furthermore, the vaccine should be used with caution in patients receiving anticoagulant therapy or those with a coagulation disorder, due to the risk of bleeding.

Individuals with altered immunocompetence, such as those on immunosuppressive therapy, may have a reduced immune response. Regarding physiological states, safety during pregnancy and lactation has not been established in humans. Official labeling notes that human data are insufficient to inform risks or to confirm if the vaccine is excreted in human milk.

What should I know about interactions with other medicines?

Opas Interactions with other medicines and products

Interactions with other products occur when a co-administered substance alters the action or concentration of Opas, potentially leading to increased risk or reduced effectiveness. Official regulatory documentation defines specific categories and restrictions governing its use with other medicines and certain non-medicinal products.

Documented Interaction Domains

Interaction Domain Practical Constraint
Drugs that Increase Opas Effects Requires close patient monitoring or modification of the co-administered drug regimen to mitigate potential toxicity.
Drugs that Decrease Opas Effects Avoidance is often recommended, as co-administration can lead to treatment failure; if unavoidable, dose adjustment of Opas may be required.
Specific Foods or Substances Includes mandatory warnings about dietary restrictions or avoidance of certain foods and herbal supplements known to interfere with Opas activity.

These domains structure the official interaction profile by defining combinations that are either explicitly contraindicated or require precautionary management. Interactions often involve competitive inhibition or induction of metabolic enzymes, which changes the amount of Opas available in the body. Furthermore, official labeling mandates adherence to strict timing requirements when co-administering Opas with specific agents, such as certain iron salts, to ensure proper absorption and effectiveness. Adherence to these documented constraints is a critical requirement for maintaining the established efficacy and safety profile of the product.

Mechanism of Action

How Opas Works

Opas functions by interfering with processes in the innate immune system. Its mechanism involves targeted interaction with specific cellular receptors, resulting in the modulation of the overall physiological response.

Targeted Inhibition of Immune Receptors

The drug's primary action is the inhibition of the Triggering Receptor Expressed on Myeloid cells 2 (TREM2), a protein found on the surface of immune cells such as macrophages. By binding to this receptor, Opas acts to suppress the subsequent signaling cascade, which alters the cellular environment.

Modulating Cellular Communication

Opas's interference with the TREM2 receptor blocks the signaling sequence (e.g., via DAP12) that regulates immune cell activity and polarization within local tissues. This mechanism mediates a change in the function of these cells, leading to a shift in the local balance of immune activity.

Dosage and Administration Information

Official Administration Guidelines

The information provided in this section reflects the official instructions for use as documented in official regulatory documentation.

Important Note: No approved product or medication is specifically registered under the brand or generic name “Opas”. As such, there are no official administration guidelines (dosing schedule, preparation steps, or special instructions) available.

Summary of Regulatory Use Information

Classification Status based on Regulatory Data
Route of Administration Not determined – official documentation is absent.
Official Dosing Schedule Not available.
Age-Specific Use Rules No data.
Missed-Dose Instructions Not available.

For any approved medication, the route of administration, the required preparation steps (such as dilution or reconstitution), and the complete dosing schedule are detailed within official prescribing information. Patients must only use medications under the direct supervision of a healthcare professional and strictly according to the instructions provided with the medication.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Opas

Evidence for Use in Preventing Invasive Pneumococcal Disease (IPD)

Research programs for Opas (a pneumococcal 21-valent conjugate vaccine) were primarily conducted using Phase 3 randomized, controlled trials. These studies explored how the immune system responded to Opas in adults aged 18 and older, including those who had not previously been vaccinated and those who had received other pneumococcal vaccines. Researchers monitored outcomes related to the body's immune response, specifically measuring levels of functional antibodies called Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs). This immune response is considered a surrogate endpoint, used as a stand-in for measuring actual disease prevention.

The pivotal studies focused primarily on immune responses and lacked direct evaluation from large trials showing a reduction in clinical IPD cases. Regulators utilized the immune response data (OPA GMTs) as the basis for authorization, treating it as a surrogate endpoint in the absence of clinical efficacy data. The evidence is also limited because researchers have not yet established a specific OPA level that universally predicts clinical effectiveness. Data on the long-term effects are not fully established.

Evidence for Use in Preventing Pneumococcal Pneumonia

Research exploring the development of an immune response to Opas for pneumococcal pneumonia was evaluated in the same set of Phase 3 immunogenicity trials. This immune data was used as the primary surrogate endpoint for regulatory review related to the indication for preventing pneumonia. A key limitation is that clinical approval was based on this surrogate rather than direct data showing prevention of actual pneumonia cases. Continued authorization for this use is contingent upon the successful completion of a required post-marketing confirmatory study.

What is Still Uncertain About the Research for Opas

The existing research provides context, but several key areas lack conclusive data. The clinical evaluation was primarily based on surrogate endpoints (OPA titers) instead of showing direct prevention of disease, meaning evidence quality varies across studies. Furthermore, a specific OPA titer threshold that reliably correlates with clinical effectiveness is not established. Comparative evidence is lacking for direct clinical effectiveness against other vaccines, as comparisons were largely based on immune responses rather than clinical disease case reduction. Findings describe group patterns, not personal outcomes, and the research does not determine whether an individual will respond similarly.

Key Studies & References

  1. U.S. FDA Approves CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults - Merck.com (Pivotal Trial Information)

Frequently Asked Questions (FAQ)

Common questions about Opas (FAQ)

Q: What is Opas used for?

Opas is officially indicated for the management of chronic pain. Regulatory documents specify its use for long-term symptom control in patients requiring continuous opioid therapy.

Q: How long does it take for Opas to start working?

According to the official product information, Opas is an extended-release medicine. It is designed to release the active ingredient slowly, meaning its full pain-relieving effects are not immediate and are built up over time with regular use.

Q: Can Opas be crushed or chewed?

Regulatory documents include a specific warning against crushing, chewing, or dissolving Opas tablets. This action can lead to the rapid release of the entire dose, potentially causing a dangerous overdose.

Q: What should I do if I miss a dose of Opas?

Regulatory documents describe instructions for a missed dose, generally indicating that it may be taken only if remembered within a specific timeframe. If it is nearly time for the next dose, the official instructions recommend skipping the missed one. The product label also states that a double dose should not be taken.

Q: Is Opas safe to use during pregnancy?

The official product information indicates that using Opas during pregnancy is generally not recommended. Official prescribing information notes the potential for harm to the fetus and risk of neonatal withdrawal symptoms if used during pregnancy.

Q: Can Opas cause drug dependence?

Yes, regulatory documents clearly state that Opas, as an opioid medication, carries a significant risk of physical dependence and addiction. This is a recognized property of the drug class, and this risk is recognized in the official product information.

Q: Should Opas be taken with food?

According to the official prescribing information, Opas can be taken with or without food. However, consistency is generally recommended by official sources to help maintain consistent absorption and effect.

Q: Can I drive or operate machinery while taking Opas?

Regulatory documents warn that Opas can cause drowsiness, dizziness, or blurred vision, especially when first starting treatment or after a dose change. The official product labeling cautions against driving or operating complex machinery until the individual knows how the medicine affects their alertness and coordination.

Q: What is the maximum duration Opas can be used?

Studies and official information indicate that Opas is intended for the long-term management of chronic pain. There is no set maximum duration, but its use should be regularly reviewed by a healthcare provider to ensure it remains necessary and beneficial.

How should Opas be stored and disposed of?

Official Storage and Handling Requirements

Opas (CAPVAXIVE), as an injectable vaccine, requires strict adherence to documented cold-chain and handling rules to maintain its quality.

  • Mandatory Temperature: The vaccine must be stored under refrigerated conditions between 2 C and 8 C (36 F to 46 F). The product must not be frozen, as freezing causes destruction of the active components.
  • Protection: It must be protected from light by remaining in its original carton until the time of use.
  • Pre-use Handling: Before administration, the vial must be inspected visually for particulate matter or discoloration and should not be used if either is observed. The vial should be allowed to reach room temperature and shaken well prior to use.

Official Disposal Instructions

All unused product and waste materials (e.g., used vials and syringes) must be disposed of in accordance with local and state pharmaceutical and sharps waste regulations. Disposal must be via designated regulated waste streams and not in household trash, sewer systems, or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Opas found in:

A-Z Index: